INSIGHTS ON DRUG DEVELOPMENT

• Context-First Data For Trustworthy AI In Biopharma

  Bridge the gap between AI experimentation and enterprise value. Learn how capturing structured, semantically rich data at the point of origin builds regulator-credible AI pipelines.

• Is Lipinski's Rule Of Five Still Relevant In Drug Development?

  Some drugs violate multiple Ro5 elements but remain developable, while some molecules adhere strictly to the Ro5, but their properties are not conducive to development.

• Spray Dried Dispersions In Controlled Release Formulations

  Integrating spray dried dispersions with CR strategies addresses poor drug solubility and the need for tailored release kinetics. Explore considerations to ensure stability and sustained supersaturation.

• Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development

  Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.

• Assessing Viability And Real-Time Apoptosis/Necrosis

  3/17/2025

  Malignant gliomas are aggressive brain tumors that resist standard treatments. Discover why researchers focus on real-time cell death dynamics to develop targeted therapies and promising strategies.

• High-Throughput Pyrogen Testing In A Multimode Microplate Reader

  3/20/2026

  Explore a faster, high‑sensitivity approach to pyrogen detection that uses an NF‑κB reporter system to measure both endotoxin and non‑endotoxin contaminants to enable shorter workflows.

• Leveraging Softgel To Extend Vinorelbine's Lifecycle, Improve Patient Convenience

  3/20/2026

  Develop innovative oral formulations of traditionally intravenous therapies to enhance patient convenience, ensure consistent systemic exposure, and support long-term brand value and market differentiation.

• ADC Development Grows More Complex — SPR Insights Bring Clarity

  4/14/2026

  Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

• Patented Process For Intermediates Useful For Deucravacitinib

  3/13/2026

  Discover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.